Search

Your search keyword '"Tsai, C-M."' showing total 449 results

Search Constraints

Start Over You searched for: Author "Tsai, C-M." Remove constraint Author: "Tsai, C-M."
449 results on '"Tsai, C-M."'

Search Results

1. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

4. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

8. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

29. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

31. Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)

32. A simple method to characterize the afterpulsing effect in single photon avalanche photodiode.

39. On material removal capability of abrasive particle in polishing process

40. Thermal annealing of Pd/inAIAs schottky contacts for transistor buried-gate technologies.

41. Compositional disordering of InGaAs/GaAs heterostructures by low-temperature-grown GaAs layers.

42. Investigation of indium doping in InGaAs/GaAs/AlGaAs graded-index separated confinement heterostructure lasers.

43. Role of cladding layer thicknesses on strained-layer InGaAs/GaAs single and multiple quantum well lasers.

46. Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)

47. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)

48. Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC) : RADIANT trial

49. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC) : RADIANT results

50. Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial

Catalog

Books, media, physical & digital resources